Boston-area biotech ImmuneID has gone through a recent restructuring and is searching for partners on its platform, which was born out of the same Harvard lab as TScan Therapeutics.
WALTHAM, Mass., Oct. 17, 2022 /PRNewswire/ -- ImmuneID, a biopharmaceutical company that leverages existing antibody responses to rapidly unveil the complexities of the immune system, thereby revealing pathways leading to precise, transformative therapies, today announced the appointment of Jessica Atkinson as Chief Business Officer, where she will oversee business activities as part of ImmuneID leadership with dual goals of advising on the company's current direction and exploring and maximizing external collaboration opportunities for its aiSPIRE platform.
ImmuneID, a biopharmaceutical company that leverages existing antibody responses to rapidly unveil the complexities of the immune system and reveal...
WALTHAM, Mass., March 31, 2022 /PRNewswire/ -- ImmuneID, a biopharmaceutical company that leverages existing antibody responses to rapidly unveil the complexities of the immune system and reveal pathways leading to precise, transformative therapies, today announced strategic partnerships with two world-class healthcare research organizations. These partnerships will significantly advance ImmuneID's work to comprehensively profile immune system responses, unveil new targets for drug development, identify clinical biomarkers and disease sub-populations, and determine the root cause of disease.
WALTHAM, Mass., Feb. 1, 2022 /PRNewswire/ -- ImmuneID - a biopharmaceutical company that uses existing antibody responses to rapidly unveil the complexities of the immune system, thereby revealing pathways leading to precise, transformative therapies - today announced the appointment of Jeremiah Degenhardt, Ph.D., as Senior Vice President, Computational Biology. In this new role, Dr. Degenhardt will oversee the data management, bioinformatics and machine learning/AI activities at ImmuneID.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced the appointment of James S. Scibetta as Chief Executive Officer and a member of the Board of Directors. Mr. Scibetta succeeds David Donabedian, Ph.D., Venture Partner of Longwood Fund, who had been serving as CEO and will serve in an advisory capacity to the Company.